Mesoblast - Termination of coverage
Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed...
674 Views
Mesoblast - COVID-19 ARDS Phase III readout later this year
Mesoblast has initiated a 300-patient randomized, controlled Phase III trial of remestemcel-L (Ryoncil for the acute graft versus host disease...
93 Views
Mesoblast - An important next several months
It is going to be a busy next several months for Mesoblast. The company recently completed filing the biologics license application (BLA) for...
529 Views
Mesoblast - Moving closer to key catalysts
Mesoblast is approaching some very key catalysts. The company expects to complete its filing of Remestemcel-L in pediatric acute graft versus host...
1.1k Views
Mesoblast - Increasingly positive on aGvHD
With a positive primary endpoint plus 180-day data in acute graft versus host disease (aGvHD), Mesoblast is on track for its first US approval....
1k Views